Safety of titanium dioxide nanoparticles in cosmetics by B. Dreno et al.
REVIEW ARTICLE
Safety of titanium dioxide nanoparticles in cosmetics
B. Dreno,1 A. Alexis,2 B. Chuberre3, M. Marinovich4,*
1Onco-Dermatology Department, CHU Nantes, CRCINA, University Nantes, Nantes, France
2Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3L’Oreal Cosmetique Active International, Levallois-Perret, France
4Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
*Correspondence: M. Marinovich. E-mail: marina.marinovich@unimi.it
Abstract
Titanium dioxide (TiO2) is widely used in a variety of products including cosmetics. TiO2 in its nanoparticle form (nano-
TiO2) is now the only form used as an ultraviolet (UV) ﬁlter in sunscreens, but also in some day creams, foundations and
lip balms. While its efﬁcacy as a UV ﬁlter is proven in the prevention of skin cancers and sunburns, some concerns have
been raised about its safety. Indeed, considering its small size, nano-TiO2 is suspected to penetrate dermal, respiratory
or gastrointestinal barriers, disseminate in the body and therefore constitute a potential risk to the consumer. At the skin
level, most studies performed in humans or animals showed that nano-TiO2 did not penetrate beyond the outer layers of
stratum corneum to viable cells and did not reach the general circulation, either in healthy or in compromised skin. The
Scientiﬁc Committee on Consumer Safety (SCCS) considers nano-TiO2 as a non-sensitizer and as mild- or non-irritant to
skin and concludes in no evidence of carcinogenicity (supported by the European Chemicals Agency), mutagenicity or
reproductive toxicity after dermal exposure to nano-TiO2. According to the SCCS, nano-TiO2 from sunscreens does not
present any health risk when applied on the skin at a concentration up to 25%. However, the SCCS does not recom-
mend the use of nano-TiO2 in formulations that may lead to exposure of the consumer’s lungs by inhalation (sprayable
products and powders). Indeed, even if human data are sparse and inconsistent, lung inﬂammation was reported in ani-
mals. In 2016, the EU Cosmetic Regulation made nano-TiO2 as an authorized UV ﬁlter, except in products that could lead
to exposure of the lungs. After oral exposure, nano-TiO2 absorption and toxicity are limited. The incidental oral exposure
to nano-TiO2 contained in lip balms is thus not expected to induce adverse health effects.
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Introduction
Titanium dioxide (TiO2) is widely used in a variety of products
including paints, cosmetics, orthodontic composites and food.
As a food additive, it is usually used as anticaking or whitening
agent or to enhance the colour and sheen of food.1–5 In cosmet-
ics, TiO2 may be used either as a white pigment in its microcrys-
talline form only6 or as inorganic ultraviolet (UV) filter,
primarily in sunscreens, but also in some day creams, founda-
tions and lip balms, to provide protection against the known
carcinogenic effects of UV radiation.6 TiO2 as a UV filter was
used in its microparticulate form in the first marketed sun-
screens, but formulated as such, it was difficult to apply and left
a white residue after application.5 The introduction in the 1980s
of colourless, ultrafine particles of TiO2 ranging from 1 to
150 nm in size reduced these unfavourable characteristics while
maintaining the sunscreens’ photoprotective capability against
both UVA and UVB. TiO2 in its nanoparticle form (nano-TiO2)
is now the only form used as a UV filter.
While nano-TiO2 has proven its efficacy as UV filter in the
prevention of skin cancers and sunburns, some concerns have
been raised about its safety.7 First, nano-TiO2 is photoreactive
with a resulting increase in reactive oxygen species (ROS) known
to be implicated in cellular damage.8 This issue has been solved
by coating nanoparticles with alumina or silica, to quench the
production of ROS. In addition, as coating improves the disper-
sion of TiO2 nanoparticles and their compatibility with other
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ingredients within sunscreen formulations, nano-TiO2 is always
used in its coated form in cosmetics.
A second important concern was that considering its size in
the nano range, nano-TiO2 is suspected to penetrate dermal, res-
piratory or gastrointestinal barriers, disseminate in the body and
therefore to constitute a potential risk to the consumer.9
The first scientific opinion on the safety of TiO2 as a UV filter at
a maximum of 25% in cosmetic products was adopted in 2000 by
the SCCNFP.10 However, as this opinion related to TiO2 irrespective
of its particle size, the Scientific Committee on Consumer Safety
(SCCS) reviewed the safety of nano-TiO2, taking into account
abnormal skin conditions and the possible impact of mechanical
effects on skin penetration.11 The SCCS concluded in 2014 that
‘based on the currently available scientific evidence which shows an
overall lack of dermal absorption of TiO2 nanoparticles’, the use of
nano-TiO2 at a concentration up to 25% as a UV filter in sun-
screens could be ‘considered to not pose any risk of adverse effects
in humans after application on healthy, intact or sunburnt skin’.
Although sunscreens and other cosmetics providing UV pro-
tection are used through skin application, they can be available as
sprayable products, which may also expose consumer lungs to
nano-TiO2 by inhalation.
12 As the SCCS opinion dealt only with
dermal applications of nano-TiO2, the SCCS published another
opinion not recommending the use of nano-TiO2 in spray appli-
cations that could lead to exposure of the lungs to nano-TiO2 by
inhalation.13 Following this opinion, the EU Cosmetic Regulation
made nano-TiO2 an authorized UV filter, except in spray prod-
ucts.14 The International Agency for Research on Cancer (IARC)
has classified TiO2, in the bulk form, as a possible carcinogen for
humans (Group 2B) when inhaled, based on evidence in experi-
mental animals. In addition, in their last opinion published in
2018, the SCCS has concluded that the information was insuffi-
cient to allow assessment of the safety of use of nano-TiO2 in
spray applications that could lead to exposure of the lungs.12
Finally, as some manufacturers can also use nano-TiO2 in
UV-protecting lip balms that may be incidentally ingested, the
potential harmful effects of nano-TiO2 used in cosmetics should
also be considered in the context of oral ingestion.15
The objective of the present document is to review safety data
concerning nano-TiO2 in cosmetic products to provide UV pro-
tection, based on data available in the SCCS and ANSES opin-
ions and data available in the scientific literature since those
opinions were published.
Methods
The SCCS recently published several opinions related to the use
of nano-TiO2 as a UV filter.
11–13 Furthermore, the French
Agency for Food, Environmental and Occupational Health &
Safety (ANSES) recently published a collective expert appraisal
report which summarized toxicological data of nano-TiO2 after
inhalation exposure.16 These data are used in the current review.
In addition, to retrieve updated relevant articles, a systematic
search of the safety data related to skin exposure published from
1 January 2014 to 31 January 2019 was performed in the
PubMed database, by using the terms ‘titanium dioxide’ AND
‘skin’ OR ‘penetration’ OR ‘absorption’. The articles were
screened by two reviewers based on titles and abstracts; only
those dealing with the safety of nano-TiO2 were selected.
Nano-TiO2 types and physicochemical
characteristics
TiO2 particles ranging from 200 to 400 nm are mostly used to
whiten or opacify many consumer products (e.g. paints, papers,
toothpastes, sunscreens).17 Nano-TiO2 that range from 1 to
100 nm is used in particular as an automotive catalytic converter
and UV protection agent, promoting either dispersion or resis-
tance to photoactivity.17 The surface of nano-TiO2 can be modi-
fied by inorganic metal oxides (e.g. alumina and amorphous
silica) and organic molecules (e.g. polyols and dimethicone)
according to its future usage. Several types of nano-TiO2 can
therefore be produced with different physicochemical characteris-
tics such as the crystal structure (i.e. anatase and rutile phases),
shape (nanotubes, nanowires and nanosphere), particle size, sur-
face area and surface modification (e.g. surface treatment or coat-
ing).18 Depending on these characteristics, each nano-TiO2 type
will be treated specifically in the human body and has its own tox-
icity profile.17 The forms of nano-TiO2 used in sunscreens are
mostly the rutile crystal structure or a rutile/anatase combination,
rarely the anatase structure only.11 It should be pointed out that
many toxicological studies of nano-TiO2 use AEROXIDE
 P25
(Evonik, Essen, Germany), consisting mostly of nano-TiO2
<25 nm under their anatase form (80–90%), as their object of
research.19 However, P25 is generally used in catalytic and photo-
catalytic industrial purposes but not in cosmetics. Furthermore,
P25 nano-TiO2 is not coated to reduce photoactivity, whereas
nano-TiO2 used in sunscreens has surface modification like coat-
ing and consists mainly in the less photoactive rutile type. The sig-
nificance of the results of P25-based studies for risk assessment of
nano-TiO2 use in sunscreens may be therefore questionable.
19
Absorption and distribution
Dermal exposure
Dermal/percutaneous absorption in healthy skin More than 20
studies dealing with dermal penetration of nano-TiO2 in healthy
skin, performed in vitro, ex vivo or in vivo either in animals or in
humans, were analysed in detail by the SCCS in 2013–2014.11
These studies reflected ‘real life’ by using sunscreen formulations
containing TiO2. According to most of them, nano-TiO2 gener-
ally stays on the skin after application of a sunscreen formula-
tion; only a small proportion of the nanoparticles are likely to
penetrate deeper in the stratum corneum, and they do not reach
the viable epidermis or dermis cells.11 Only 2 studies suggested a
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cutaneous penetration of nano-TiO2 into the stratum granulo-
sum when using human foreskin grafts transplanted onto SCID
mice20 or in the dermis of minipigs.21 However, in the latter,
only an insignificant amount of scattered and isolated nanopar-
ticles was detected by electronic microscopy. Furthermore, con-
sidering that pigskin was shown to be up to 4 times more
permeable than human skin,22 it is difficult to extrapolate this
effect in humans in vivo. Moreover, several studies demonstrated
that nano-TiO2 does not penetrate beyond the stratum corneum
of pigskin when coated with cetyl phosphate, manganese dioxide
or trimethoxycaprylylsilane.15
The limited nano-TiO2 skin penetration to the stratum cor-
neum has been mostly confirmed by the updated literature,
including a more recent individual study performed both in vitro
and in vivo in rats23 and studies reported by the Australian Thera-
peutic Goods Administration (TGA), a part of the government
health department, in their updated scientific review report con-
cerning the safety of TiO2 and ZnO nanoparticles in sunscreens in
2016.24 The three studies reported by the Australian TGA that
were published after the SCCS opinion were performed in vitro25
or in vivo in humans.26,27 The study performed in vitro and one of
the studies performed in vivo in six subjects26 confirmed the lim-
ited nano-TiO2 skin penetration, which was not associated with
diffusion into viable cells. However, the other studies performed
in vivo in humans, which assessed repeated nano-TiO2 dermal
exposure in two subjects, did not confirm these results.27 Indeed,
7 days after application of a commercial sunscreen containing
nano-TiO2 (2 mg/cm
2 over a total skin area of 600 cm2) six times
a day, nano-TiO2 was detected beyond the stratum corneum, into
viable cells in the epidermis, with a transmission electron micro-
scope equipped with an EDX.27 Data on in vivo dermal/percuta-
neous absorption in human skin are presented in Table 1.
Dermal/percutaneous absorption in compromised skin Five
studies performed in mice (N = 1), pigs (N = 2) or humans
(N = 2) analysed in detail by the SCCS demonstrated that nano-
TiO2 contained in a sunscreen formulation did not penetrate
compromised skin, either stripped/dermabraded, sunburnt
(simulated with UVB radiations) or psoriatic.11 Even if nano-
TiO2 penetrated into deeper areas of the stratum corneum in
psoriatic skin than in healthy skin, they did not reach living cells
in either psoriatic or healthy skin11 (Table 1).
Two out of the three studies published after the SCCS opin-
ion, and assessing dermal/percutaneous absorption in compro-
mised skin, confirmed these results. The study by Xie et al.,23
performed in rats, showed that nano-TiO2 did not penetrate the
stratum corneum in skin either intact or slightly damaged with
2% sodium lauryl sulphate (SLS) solution, both in vitro and
in vivo. Moreover, in the study by Crosera et al.,25 performed on
human skin in vitro by using static diffusion cells, nano-TiO2
was only detected in the epidermis of both healthy and needle-
abraded skin samples after a 24-h exposure to a sonicated
suspension of nano-TiO2 (606 lg/cm²; Table 1). Of note, in that
study, the total amount of nano-TiO2 was similar in both
healthy and needle-abraded skin, indicating that lesions did not
increase permeation. In the third study, performed in vivo in
humans and described above, nano-TiO2 was detected in viable
cells in the epidermis, beyond the stratum corneum, in sunburnt
skin simulated with UVB radiations, 0.4 J/cm227 (Table 1).
However, these results should be considered with caution as only
one type of sunscreen was tested in only two volunteers.
Distribution after dermal exposure A study assessed the nano-
TiO2 distribution after topical application to the dorsal skin of
hairless rats for 56 days.28 Nano-TiO2 was detected in the stratum
corneum layer of the epidermis and follicular epithelium, but not
in the viable skin areas. No titanium was detected in internal
organs by inductively coupled plasma mass spectroscopy. How-
ever, the concentration of titanium was higher in the lung samples
of rats treated with nano-TiO2 than in the lung samples of control
rats. This was probably due to the inhalation of nano-TiO2.
28 A
long-term study showed a small increase in titanium level in the
liver tissue of hairless mice exposed to topical applications of sun-
screen containing nano-TiO2 once a week for 36 weeks.
29 This
increase was higher in comparison with that observed in
untreated mice, but similar to that observed in mice receiving UV
radiation after sunscreen application. The authors concluded that
this increase was possibly due to oral absorption of residual TiO2
after washing. Moreover, these results suggest that the dermal per-
meability of nano-TiO2 is not enhanced by UV radiation.
29
In conclusion, almost all in vitro, in vivo and ex vivo studies,
performed in humans or animals, showed that nano-TiO2 pene-
tration was largely limited to the stratum corneum. With the
exception of one study, nano-TiO2 did not penetrate into the skin
beyond the surface layers to viable cells and did not reach the gen-
eral circulation, either in healthy or in compromised skin.
According to studies performed in rodents, nano-TiO2 distribu-
tion after dermal exposure is very limited and probably due to
inhalation or oral exposure.
In 2014, the SCCS11 concluded that nano-TiO2 at a concen-
tration up to 25% as a UV filter in sunscreens can be considered
not to pose any risk of adverse effects in humans after applica-
tion on healthy, intact or sunburnt skin. Results published after-
wards support the SCCS conclusions.
Inhalation exposure
Absorption after inhalation exposure In 2015, the SCCS13 indi-
cated that considering the size of nanoparticles, there are con-
cerns about whether inhaled airborne nanoparticles are safe,
particularly from spray products that could lead to exposure of
the consumer’s lungs to nano-TiO2 by inhalation.
Due to their size, inhaled nanoparticles are mainly found in
the upper airways (nose, mouth, pharynx, larynx and trachea),
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but they can also reach the deeper lungs and deposit in alveoli. In
general, cough and mucociliary clearance quickly remove particles
from most upper airway areas (t1/2 in healthy humans: 2–4 h),
while in the lung periphery alveolar macrophages slowly clear par-
ticles.30 Of note, it is estimated that about 10% of insoluble parti-
cles remain in human lungs due to the very slow clearance rate.30
Distribution after inhalation exposure Studies assessing the dis-
tribution of nano-TiO2 after inhalation exposure and analysed
in the ANSES report16 were performed in rodents, mainly in rats
using mostly P25 nano-TiO2 which are not utilized in cosmetic
applications. Therefore, the results of P25-based studies may not
be transferable to the nano-TiO2 forms used in sunscreens.
19
In the lungs of female Wistar rats, the presence of nano-TiO2
was reported in alveolar macrophages and, to a lesser extent, in
pneumocytes.31 In the absence of pulmonary overload, the expo-
sure duration does not seem to impact either the lung distribu-
tion of nano-TiO2 or its half-life,
32,33 estimated at 2 months.34
Nano-TiO2 may translocate to other organs to a limited extent.
In several studies, nanoparticles were detected in the liver, heart,
kidneys, pancreas, spleen, brain or blood after inhalation and
translocation through the lung barrier.31,35–38 Nevertheless, this
phenomenon does not appear to be predominant as the translo-
cation rate is slower than the lung clearance rate.39
In conclusion, inhaled nanoparticles can be found in the
lungs. Inhaled nano-TiO2 is capable of diffusing across the lung
barrier and translocating throughout the body even if this phe-
nomenon seems to be limited.
Oral exposure
Absorption after oral exposure As the ingredients used in lip
balms may be incidentally ingested, it is necessary to consider
the potential ability of nano-TiO2 to penetrate oral and gastroin-
testinal mucosa. Currently available data were retrieved from
studies performed in pigs, rats and humans.
Using an ex vivo model of porcine oral mucosa, nano-TiO2
was shown to rapidly interact with the mucous layer, penetrate
the oral epithelium and impact on the physiological homeostasis
of buccal/sublingual cells in the oral cavity.40 Three studies per-
formed in vivo in rats showed that oral administration of nano-
TiO2 either led to extremely low systemic absorption of nano-
TiO2 from the gastrointestinal tract
35,41 or did not lead to signif-
icant nano-TiO2 absorption.
42 The nano-TiO2 dose absorbed
across the intestinal barrier was estimated to be about 0.6%,
0.2% and 0.05% of the administered dose only, respectively, 1 h,
4 h and 7 days after administration.35 In humans, a 3D organ-
otypic human buccal mucosa model was used to access nano-
TiO2 penetration in vitro. Nano-TiO2 penetrated the reconsti-
tuted human normal buccal epithelium, with most of the parti-
cles remaining in the upper third of the epithelial tissue.43
Another study assessed gastrointestinal absorption of nano-TiO2
in vivo: a single dose of nano-TiO2 (5 mg/kg bw), dispersed in
water, was administered to nine subjects. Only negligible absorp-
tion of nano-TiO2 via the gastrointestinal tract was observed
after 2, 4, 24 and 48 h.44
Currently available data thus showed nano-TiO2 penetration
through in vitro/ex vivo models of oral mucosa, but negligible
nano-TiO2 absorption, if any, via the gastrointestinal tract after
oral exposure to nano-TiO2 in vivo, either in rats or in humans.
Distribution after oral exposure Two studies performed in
rodents were analysed in a study report from INERIS (French
National Institute for Industrial Environment and Risks).45 The
study performed in mice showed that 2 weeks after a single
administration of nano-TiO2 (25 and 80 nm, column/spindle
shape, 5 g/kg bw, gavage), particles mainly accumulated in the
liver, spleen, kidneys and lungs.46 The very high nano-TiO2 dose
used in this study is not representative of human exposure.47 In
contrast, the study performed in rats did not show any significant
increase of titanium in liver, spleen, kidney and even brain in
comparison with the vehicle control group, and no dose–response
relationship was observed after nano-TiO2 (264.4, 520.8 and
1041.5 mg/kg bw/day) was orally administered daily for
13 weeks.41 However, a more recent study using radiolabelled
nano-TiO2 showed nano-TiO2 distribution in rat liver, lungs, kid-
neys, brain, spleen, uterus and skeleton 7 days after administra-
tion of a single dose of nano-TiO2 (about 40 lg/kg bw), even if
the estimated absorbed dose was low (0.09–0.98 ng/g depending
on the organ).35 These results suggested that upon repeated long-
term oral exposure, nano-TiO2 may accumulate in specific organs
and thereby present a risk in humans who are orally exposed to
nano-TiO2.
In conclusion, following oral intake, nano-TiO2 can poten-
tially permeate the gastrointestinal lining but to a limited extent.
Toxicity
Cytotoxicity
Skin cells Most in vitro studies used the human keratinocyte
HaCaT cell line to assess nano-TiO2 skin cytotoxicity.
24,32 Two
studies analysed by the TGA reported decreased cell viability of
HaCaT cells after in vitro exposure to nano-TiO2.
25,48 Doses var-
ied from 0.007 to 50 lg/cm2 or from 1 to 100 lg/mL and the
exposure duration from 24 h to 7 days. When several nano-
TiO2 concentrations were tested, a dose-dependent effect was
observed. On the contrary, five studies reported no effect of
nano-TiO2 (0.1–25 lg/cm
2 or 1–100 lg/mL) on HaCaT cell via-
bility after 2–24 h of exposure,49–53 but one of them showed a
dose-dependent increase in apoptosis.52 Data on nano-TiO2
cytotoxicity assessed in human skin cells are presented in
Table 2. Except for the study by Crosera et al., all these studies
assessed ROS formation and all of them showed that nano-TiO2
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induced ROS and suggested that these components would be
responsible of nano-TiO2 cytotoxicity. ROS induction in HaCaT
cells was shown to be enhanced by UVA50 and UVB49 irradia-
tion, but not by UVC irradiation,52 thus demonstrating photo-
toxicity of nano-TiO2 to human skin keratinocytes.
Interestingly, after UVA irradiation, either less or no phototoxic-
ity was observed in HaCaT cells with the rutile form of nano-
TiO2 in comparison with the anatase form.
50,51 Of note, no
phototoxicity was observed with the anatase form of nano-TiO2
in the EpiDerm
TM 3D skin model51 In contrast to the HaCaT cell line
that consists of human immortalized keratinocytes, the Epi-
DermTM 3D model is a reconstructed human epidermis with nor-
mal human-derived epidermal keratinocytes that is expected to
provide a more integrated response.
In 2013–2014, the SCCS indicated that surface coating of
nano-TiO2 was very important to reduce its phototoxicity.
11
Table 2 Nano-TiO2 cytotoxicity assessed in the HaCaT human keratinocyte cell line'
References Nano-TiO2 type Dose Exposure time Assay Cytotoxic effect/
Reduced cell
viability
Effective
concentration
Rancan
et al.49
Anatase
(10  2 nm),
uncoated (gift)
10–500 lg/mL 2 h XTT† NO NA
Yin et al.50 Anatase (<25 nm
and 325 mesh),
rutile (<100 nm;
Sigma) and P25
(anatase/rutile
mixture, 86%/
14%; Degussa)
50 and 100 lg/mL
(sonicated)
4 h MTS‡ NO NA
Horie et al.51 Anatase (Ishihara
Sangyo Kaisha
Ltd.; Tayca
Corporation) and
rutile (Tayca
Corporation)
100 lg/mL
(sonicated)
6, 24 h WST-1† and LDH§ NO NA
Tucci et al.53 Anatase (Sigma) 5, 50 and 100 lg/
mL (sonicated)
24 h PI¶ NO†† NA
Wright et al.52 Anatase H2TiO7
(12 nm; gift)
0.1, 1, 10 and
25 lg/cm2
(sonicated)
24 h MTT‡‡ NO NA
12 h, 24 h Hoechst 33342§§ YES, CC-
dependent
increase in
apoptosis¶¶
0.1–10 lg/cm2
(about 40–65% at
12 h/50–80% at
24 h)
Crosera
et al.25
Anatase/rutile
mixture, 90%/
<10%††† (Sigma
Aldrich)
0.007–50 lg/cm2
(sonicated)
24 h, 48 h, 7 days MTT‡‡ YES, very low,
CC-dependent,
ET-independent
Min = 5.5 lg/cm2
EC50 = 44 lg/cm
2
(95% CL: 31–62 lg/
cm2; 7 days)
Alamar Blue‡‡ YES, slightly
higher vs. MTT
assay, CC-
dependent, ET-
dependent
Min = 0.6 lg/cm2
EC50 = 1.9 lg/cm
2
(95% CL = 1.3–
2.7 lg/cm2; 7 days,
highest effect).
7 days PI¶ YES, CC-
dependent
Min = 5.5 lg/cm2
EC50 = 38 lg/cm
2
(95% CL = 31–
47 lg/cm2)
Gao et al.48 P25, anatase/
rutile mixture
(5–6 nm;
Degussa)
1–100 lg/mL 24 h MTT‡‡ YES, CC-
dependent
Min = 0.5 lg/mL
Max = 100 lg/mL
(77%)
†Mitochondrial activity. ‡Activity of (mainly mitochondrial) dehydrogenases. §Cell membrane damage (release of cytosolic LDH). ¶Index of necrotic or late
apoptotic cell death. ††No signiﬁcant differences neither in cell death nor in cell cycle proﬁle vs. control cells. ‡‡Cellular viability. §§Apoptosis. ¶¶No effect
with the 25 lg/cm2 dose. †††Nano-TiO2 size distribution centred on the value of 38 nm.
Abbreviations: CC, concentration; CL, conﬁdence limit; EC50, half-maximal effective concentration; ET, exposure time; LDH, lactate dehydrogenase;
MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide; NA, not applicable; PI, propidium iodide; WST-1, 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium; XTT, 2,3-Bis-
(2-methoxy 4-nitro-5-sulfophenyl)-2H-tetrazolium5-carboxanilide salt.
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Lung cells Four studies analysed in the review by Zhang et al.32
used the human lung cancer A549 cell line to assess nano-TiO2
inhalation or pulmonary cytotoxicity in vitro. All of them showed
that nano-TiO2 induced oxidative stress and/or apoptosis.
32
In conclusion, cytotoxicity of nano-TiO2 seems to be medi-
ated by ROS production and enhanced by UVA or UVB irradia-
tion in vitro. Interestingly, less or no phototoxicity was observed
in a human keratinocyte cell line with the rutile form of nano-
TiO2 in comparison with the anatase form, and no phototoxicity
was observed with the anatase form in a 3D human skin model.
Surface coating of nano-TiO2 reduces its phototoxicity. It should
be noted that P25 nano-TiO2 is uncoated and generally used
commercially for catalytic reactions and not for cosmetic appli-
cations.
Dermal toxicity
No studies relevant for the assessment of acute dermal toxicity
of nano-TiO2 are available.
11
Concerning skin sensitization, results of the three studies per-
formed in guinea pigs and analysed by the SCCS showed that
nano-TiO2 was a non-sensitizer.
11 These results were confirmed
by more recent studies reported by the TGA.24 Indeed, two stud-
ies performed in mice showed no skin sensitization after dermal
application of nano-TiO2 on the ears for 3 days.
1,54 However,
nano-TiO2 was shown to increase dermal sensitization induced
by 2,4-dinitrochlorobenzene.54
Concerning skin irritation, the studies analysed by the SCCS
provided only limited relevant information.11 From the seven
studies performed in guinea pigs (N = 1) or rabbits (N = 6),
only four performed in rabbits were relevant. Indeed, as the
TiO2 particle size was not specified in the three other studies, the
‘nano’ size could not be assured. Nano-TiO2 of anatase/rutile
types coated with trimethoxy-n-octyl-silane was used in two
studies, and the results were not consistent: neither erythema
nor oedema were observed in one study, while very slight ery-
thema and oedema were observed 1 day after skin patch applica-
tion in the other study. The two other studies, in which the
proportion of nano-TiO2 was not specified, evaluated 5-day
repeat applications and showed slight irritation (mean irritation
scores: 0.13–1.92). In one more recent study reported by the
TGA,24 neither erythema nor oedema was observed in rabbits
after dermal exposure to 0.5 g of nano-TiO2 for 4 h.
55 In the
same study, and no skin irritation was observed using a 3D
human skin model (KeraSkinTM; Modern Cell & Tissue Technol-
ogy, Seoul, Korea) after application of nano-TiO2 at a final con-
centration of 25% (w/v).55 Likewise, no signs of dermal
irritation were observed after exposure of another human 3D
skin model derived from epidermal keratinocytes (EpiDermTM)
to 1 mg/mL of four nano-TiO2.
56
In conclusion, nano-TiO2 is considered as mild- or non-irri-
tant to skin.11
Inhalation exposure
Data reported below come from the ANSES report.16 Most of
the data focus on studies performed with the P25 form,
which consists of nano-TiO2 only (anatase: 80–90%/rutile:
20–10%), generally used in several catalytic and photo-
catalytic industrial applications and not in cosmetic applica-
tions.
Acute toxicity Pulmonary effects. Six acute toxicity studies,
either performed in mice (N = 4)57–60 or in rats (N = 2),61,62
assessed pulmonary effects after nano-TiO2 inhalation. Of them,
one reported irritation60 and three reported mild or moderate
pulmonary inflammation, with or without histopathological
changes.58,60,61
Microvascular effects. Six studies, all performed in rats by the
same research team, investigated the effects of nano-TiO2 on the
microvascular system by assessing arteriolar responsiveness.63–68
In these studies, acute inhalation of nano-TiO2 (P25, primary
particle size 21 nm, 1.5–20 mg/m3 for 4–12 h to achieve a pul-
monary deposition of 4–90 lg) impaired vasodilation in the sys-
temic microcirculation (arterioles of the spinotrapezius
muscle,63,64 subepicardial arterioles,65 coronary arterioles66 and
uterine arterioles68). This alteration was due to endothelial dys-
function mediated by the production of free radicals, thus
reducing the bioavailability of nitric oxide.64,66,67
Repeated dose toxicity Animal data. Pulmonary effects—Five
repeated inhalation toxicity studies using multiple nano-TiO2
concentrations (from 0.5 to 10.0 mg/m369 or 2 to 50 mg/m370
for 5 days or from 0.5 to 1.84 mg/m334 or 2.5 to 10.0 mg/m371
for 4 weeks or from 0.5 to 10.0 mg/m3 for 13 weeks33) showed
pulmonary inflammation either in mice or in rats, but not in
hamsters. Lung histopathological changes were highlighted in
rats.33,34,70 Moreover, hypertrophy/hyperplasia of the bronchi
and bronchioles70 or preneoplastic effects such as metaplasia33
were also observed in rats exposed to the highest nano-TiO2
concentration (10 mg/m3 for 13 weeks or 50 mg/m3 for 5 days,
respectively). Other studies conducted using a single concentra-
tion confirmed these results, qualitatively or quantitatively.31,72
Results observed in rats only can be due to lung overload, a phe-
nomenon that results from impairment of lung clearance. It
seems to be specific to rats exposed to poorly low-toxicity parti-
cles like TiO2.
73
Cardiovascular effects—Five repeated inhalation toxicity studies
or instillation studies performed in mice (N = 4)74–77 or rats
(N = 1)78 were analysed. In mice, repeated long-term expo-
sure to nano-TiO2 (1.25, 2.5 or 5 mg/kg bw for 9 months)
was associated with atherosclerosis.75 Another study showed
increased plasma levels of serum amyloid A (SAA, a known
risk factor for cardiovascular diseases that accelerates
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atherosclerotic plaque development) in pregnant mice
exposed to 42 mg/m3 of nano-TiO2 for 11 days.
74 Two stud-
ies performed in ApoE knock-out mice, an atherosclerosis-
susceptible animal model, resulted in conflicting results: on
the one hand, exposure to nano-TiO2 (0.5 mg, 2.5 mg and
5 mg/kg bw/week for 6 weeks) induced endothelial and lipid
metabolism dysfunction, contributing to atherosclerosis pro-
gression,77 and on the other hand, exposure to nano-TiO2
(0.5 mg/kg bw/week for 4 weeks) was associated with modest
plaque progression and was not associated with either inflam-
mation or vasodilatory dysfunction.76 In pregnant rats,
microvascular dysfunction was observed after exposition to
about 11 mg/m3/h, 5 h/day for 7–9 days. Of note, high doses
of nano-TiO2 (10–42 mg/m
3) were used in most of these
studies.
Effects on the immune system—The effects of nano-TiO2 on the
immune system were evaluated in many studies. Some showed
disturbance of the immune system in rats (e.g. increased CD4+/
CD8+ ratio,79 increase in NK cells number80 and activity81), but
it seems difficult to conclude with respect to the immunotoxicity
of nano-TiO2 due to the variability of protocols and exposure
routes (aerosolized, inhalation, intranasal exposure and nose-
only application).
Neurotoxicity—The eight analysed studies performed in
mice82–89 showed various effects of nano-TiO2 on the nervous
system: histological changes in the hippocampus and cerebral
cortex,82–84,87 proliferation of glial cells, necrosis, signs of cell
degeneration,86,87 as well as dysregulation of genes related to
oxidative stress.85,86 Moreover, nano-TiO2 impaired spatial
recognition memory in mice.87,88 Nano-TiO2 toxicity on the
brain, especially on the hippocampus, seems to be dose-
dependent.87,88
In rats, the study by Horvath et al.90 showed a significant
slow-down of sensory evoked potentials and tail nerve action
potential, and the study by Disdier et al.91 evidenced a decreased
expression of a neuronal activity marker (synaptophysin), exac-
erbated in older rats even if TiO2 nanoparticles were not
detected in the brain.
Liver toxicity—Liver toxicity was investigated in two studies
which did not report the same results. No liver toxicity was
observed in a transcriptomic analysis after a 10-day inhalation
challenge with 42 mg/m3 of nano-TiO2 in mice,
72 while oedema
and cytoplasmic loss of hepatic cells were observed after instilla-
tion exposure to 0.5, 4 and 32 mg/kg bw of nano-TiO2 for
4 weeks in rats.79
Kidney toxicity—In mice, histopathological changes including
tubular dilatation and necrosis, as well as increased oxidative
stress and alterations in renal function markers, were reported
after instillation of nano-TiO2 (0.5 mg/week for 4 weeks) in the
only study that assessed kidney toxicity.92
Human data. In humans, eight studies assessed nano-TiO2 toxi-
cological effects on workers exposed to nano-TiO2 by inhala-
tion.93–100 Results suggested possible pulmonary and
cardiovascular effects. Nevertheless, no causal link between TiO2
inhalation exposure and the observed effects could be established
in these studies.
In conclusion, several studies performed in rodents showed
nano-TiO2 toxicity at several levels (pulmonary inflammation,
cardiovascular effects and neurotoxicity), mainly using high
doses of nano-TiO2 far exceeding human exposures, including
cases of occupational exposure. Moreover, results observed in
rats at the pulmonary level can be due to lung overload. Results
concerning liver and the immune system were inconsistent, and
only one study dealt with kidney toxicity. No conclusion can be
drawn in humans as no causal link could be established between
TiO2 inhalation exposure and the possible pulmonary and car-
diovascular observed effects, in addition to several biases that
limit the interpretation of some studies.
Oral exposure
Acute toxicity Acute toxicity was shown in a study performed
in female mice exposed to a very high nano-TiO2 dose (5 g/kg
bw, gavage): increase in relative liver weight in comparison with
the control group, hepatic inflammatory response, slight
histopathological alterations of the liver and kidneys, and
increased levels of enzymatic biomarkers of cardiac lesions.46
Otherwise, studies performed in rodents usually show low oral
acute toxicity of nano-TiO2 with lethal dose (LD)50 values higher
than 2150 mg/kg bw or even 5000 mg/kg bw.11,45,101
Repeated dose toxicity Some rodent studies showed nano-
TiO2 toxicity at several levels: immune system,
102 central ner-
vous system,88,103 kidneys,104 liver,105 spleen106 and fertil-
ity.107,108
In rats, nano-TiO2 (10 mg/kg bw/day, 7 days, gavage) was
shown to increase dendritic cells frequency in Peyer’s patches
but not in the spleen. No intestinal inflammation was reported,
and no (in vivo) or limited (in vitro) effects were observed on
Treg and Th cell subsets.102 All other studies were performed in
mice. Nano-TiO2 (0.5, 10 and 50 mg/kg bw/day for 60 days or
2.5, 5 and 10 mg/kg bw/day for 90 days, respectively) impaired
neurofunction and spatial recognition memory behaviour.88,103
Kidney toxicity was also evidenced after intragastric administra-
tion of nano-TiO2 (2.5, 5 and 10 mg/kg bw/day for 90 days),
with an inflammatory response and cell necrosis.104 In the liver,
histopathological changes were observed after oral administra-
tion of 250 mg/kg bw/day of nano-TiO2 for 30 days; no effect
was observed with both lower tested doses (62.5 and 125 mg/kg
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bw/day). Moreover, dose-dependent increased enzymatic activi-
ties were observed in the 125 and 250 mg/kg bw/day groups.105
Nevertheless, those high doses do not reflect the possible human
exposure. In another study, splenic damage was observed with
lower nano-TiO2 doses (10 mg/kg bw/day for 15, 30, 45, 60, 75
or 90 days, gavage), with time-dependent inflammation and cell
necrosis.106 Two 90-day repeated exposure studies evaluated the
effects of nano-TiO2 (2.5, 5 and 10 mg/kg bw/day, gavage) on
fertility in mice.107,108 In females, dose-dependent decreased fer-
tility (mating rate, pregnancy rate and number of newborns),
ovarian inflammation and follicular atresia were reported.107 In
males, testicular lesions, sperm malformations and altered serum
sex hormone levels were observed.108
In conclusion, studies performed in rodents showed low oral
acute toxicity of nano-TiO2 except one study using very high
doses. Repeated dose studies showed nano-TiO2 toxicity at vari-
ous levels (central nervous system, kidney, spleen and gametes),
but the doses used were far higher than those to which humans
can be exposed in the context of an incidental oral exposure
through cosmetic use.
Mutagenicity/genotoxicity
The genotoxic potency of nano-TiO2, assessed both in vitro
(cells, tissues) and in vivo (rodents) was largely reported in many
reviews.11,16,24 Various forms of nano-TiO2, with different
shape, size, coating, surface reactivity, charge and crystallinity,
were used, and the results of all these studies are inconsistent.
Some of them demonstrated that nano-TiO2 could cause DNA
damage and that the genotoxic effect would be due to a sec-
ondary mechanism of action involving free radicals.16 Of note,
free radical production is limited in sunscreens due to nano-
TiO2 coating and the potential presence of antioxidants.
24 More-
over, many studies showed that nano-TiO2 did not reach viable
skin cells after topical application, and genotoxic effects were
only observed with high concentrations of nano-TiO2 after oral
or inhalation exposure in animals. Consequently, nano-TiO2 can
be considered as a weak genotoxic agent, as do national and
international governmental organizations (ANSES, IARC,
NIOSH and OECD).
Therefore, nano-TiO2 in the form and size used in cosmetics
is unlikely to be genotoxic.
Carcinogenicity
Dermal exposure Three studies performed in mice (N = 1),
rats (N = 1) or both (N = 1) were evaluated in detail by the
SCCS in 2013–2014.11 In mice, no carcinogenic promoter activ-
ity was observed with uncoated nano-TiO2 in both studies.
109,110
Likewise, no carcinogenic promoter activity was observed with
alumina-coated or stearic acid-coated nano-TiO2. However, an
increase in the number of tumours was found among mice trea-
ted with silica-coated nano-TiO2.
110 Nevertheless, as this
increase was not significant and positive controls were lacking,
no conclusion could be drawn. In rats, no conclusion could be
drawn from both studies due to the absence of any positive con-
trols and the lack of experience with the models used.110,111
These results on carcinogenicity through dermal exposure are
therefore inconclusive. However, as there is no cutaneous pene-
tration beyond the surface layers, there is no systemic risk. The
Committee for Risk Assessment [RAC, European Chemicals
Agency (ECHA)] considers that there is no experimental evi-
dence for TiO2 carcinogenicity for the dermal route.
112
Inhalation exposure Only one study performed in 1995 investi-
gated the carcinogenic potential of nano-TiO2 after inhalation
exposure in animals. The results showed an increase in the inci-
dence of lung tumours in rats but not in mice exposed to
repeated doses of nano-TiO2 (7.2 mg/m
3 for 4 months followed
by 14.8 mg/m3 for 4 months and 9.4 mg/m3 for 5.5 months
[mice] or 16 months [rats]).113 Among three studies investigat-
ing the carcinogenic potential of nano-TiO2 after instillation
exposure,114–116 only one confirmed the nano-TiO2 promotor
potential.116
In humans, a potential relationship between exposure to TiO2
and the occurrence of cancers was assessed in seven epidemio-
logical studies.117–123 An increase in death due to lung cancer
was reported in most of these studies, although no causal rela-
tionship could be established.
We can conclude from the study of Heinrich et al.113 that
nano-TiO2 (P25 as material tested) is a lung carcinogen in rats
at a concentration resulting in pulmonary inflammation and
altered clearance. This is consistent with the previous nano-TiO2
classification as suspected/possible carcinogen in humans by
other organizations [IARC, NIOSH and RAC (ECHA)]. Never-
theless, results obtained with the P25 form of nano-TiO2 cannot
be extrapolated to other forms of nano-TiO2, and the concentra-
tions used greatly exceed maximum human exposure.
Oral exposure The few available data do not seem to indicate
any nano-TiO2 carcinogenic promoter activity after oral expo-
sure.45 The Committee for Risk Assessment (RAC) also consid-
ers that there is no experimental evidence for TiO2
carcinogenicity for the oral route.112
Reproductive toxicity
Dermal exposure According to the SCCS, there is no relevant
study on reproductive toxicity after dermal exposure to nano-
TiO2.
11,15
Inhalation exposure Nine studies, performed in mice
(N = 4)124–127 or rats (N = 5),78,128–131 suggest a possible effect
of pre- or peri-natal inhalation exposure to nano-TiO2. In mice,
lung inflammation was reported in the gestating females,124 and
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moderate neurobehavioural changes124 as well as gene expres-
sion in female liver were reported in the offspring.127 In the F1
generation, a trend in reduced sperm counts was also
observed.126 However, sex ratio or viability did not seem to be
impaired. In rats, a decrease in the litters’ height and weight was
reported after inhalation exposure of gestating females to
10 mg/m3 of nano-TiO2 for 11 days. However, this was not the
case when gestating females were exposed for 7 or 8 days.
Microvascular and cardiac changes,78,128,131 and effects on cogni-
tive and behavioural functions130 were observed in the offspring.
Oral exposure Both studies reported hereafter were performed
in rats. Abnormal lung development with macrophage infiltra-
tion was reported in neonates at term, i.e. 9 days after the last
nano-TiO2 dose administered to pregnant females (200 mg/kg
bw/day, gavage from the 6th to the 12th day of gestation).132
Neurotoxic effects of nano-TiO2 were also reported: reduced cell
proliferation in the hippocampus of the neonates and impaired
learning and memory in offspring aged 60 days were observed
after administration of nano-TiO2 to pregnant females (100 mg/
kg bw/day, gavage from the 2nd to the 21st day of gestation).133
Conclusion
According to the information reported in this review, nano-
TiO2 is considered as a non-sensitizer and as mild- or non-
irritant to skin. Moreover, there is no evidence of carcino-
genicity, mutagenicity or reproductive toxicity after dermal
exposure to nano-TiO2. Nano-TiO2 exhibits in vitro cytotoxi-
city, apparently mediated by ROS production and enhanced
by UVA or UVB irradiation. However, no cytotoxic effect
was reported using a 3D human skin model, and nano-TiO2
used in cosmetics is usually coated to decrease ROS produc-
tion. Above all, as nano-TiO2 does not seem to penetrate the
skin beyond the surface layers to viable cells and does not
reach the general circulation after application to either
healthy or compromised skin, nano-TiO2 from sunscreens
does not appear to present any health risks when applied on
the skin at a concentration up to 25%.
However, the SCCS does not recommend the use of nano-
TiO2 in formulations that may lead to exposure of the con-
sumer’s lungs by inhalation, i.e. sprayable products and pow-
ders. Indeed, even if human data are sparse and inconsistent,
lung inflammation was reported in animals.
After oral exposure, nano-TiO2 absorption and toxicity seem
to be limited. The incidental oral exposure to nano-TiO2 con-
tained in lip balms is thus not expected to induce adverse health
effects.
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